Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Free Report) CFO William J. Peters sold 7,426 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $386,523.30. Following the transaction, the chief financial officer now owns 94,103 shares in the company, valued at approximately $4,898,061.15. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Amphastar Pharmaceuticals Trading Up 4.8 %
NASDAQ AMPH opened at $48.31 on Monday. The firm has a market cap of $2.35 billion, a PE ratio of 16.10, a price-to-earnings-growth ratio of 1.02 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The company has a 50 day moving average price of $48.44 and a 200 day moving average price of $44.23.
Institutional Trading of Amphastar Pharmaceuticals
Institutional investors have recently made changes to their positions in the business. Silvercrest Asset Management Group LLC raised its stake in Amphastar Pharmaceuticals by 35.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock valued at $4,937,000 after buying an additional 29,182 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the third quarter valued at about $11,070,000. Intech Investment Management LLC purchased a new position in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $426,000. Granite Investment Partners LLC boosted its stake in Amphastar Pharmaceuticals by 12.7% in the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after purchasing an additional 44,744 shares in the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new stake in Amphastar Pharmaceuticals during the 2nd quarter worth approximately $93,000. Institutional investors and hedge funds own 65.09% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Analysis on AMPH
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Featured Stories
- Five stocks we like better than Amphastar Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- California Resources Stock Could Be a Huge Long-Term Winner
- Using the MarketBeat Dividend Yield Calculator
- Observability Wars: Datadog and Dynatrace Vie for Data Dominance
- Golden Cross Stocks: Pattern, Examples and Charts
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.